S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)

Apollo Endosurgery Stock Forecast, Price & News

-0.34 (-5.44%)
(As of 01/14/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
752,216 shs
Average Volume
315,480 shs
Market Capitalization
$169.63 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive APEN News and Ratings via Email

Sign-up to receive the latest news and ratings for Apollo Endosurgery and its competitors with MarketBeat's FREE daily newsletter.

Apollo Endosurgery logo

About Apollo Endosurgery

Apollo Endosurgery, Inc. is a medical technology company, which focuses on the design, development, and commercialization of medical devices to advance gastrointestinal therapeutic endoscopy. It offers Endoscopy, Surgical and Other products. The firm's endoscopy product portfolio consists of the OverStitch Endoscopic Suturing System, OverStitch Sx Endoscopic Suturing System, and Orbera Intragastric Balloon System. Its products are used by gastroenterologists and bariatric surgeons in a variety of settings to treat multiple gastrointestinal conditions including closure of acute perforations and chronic fistulas; inadvertent perforation of the GI tract; tissue closure after the removal of abnormal lesions in the esophagus, stomach or colon; the treatment of swallowing disorders; esophageal stent fixation and obesity. The company was founded by Christopher J. Gostout and Dennis L. McWilliams in 2005 and is headquartered in Austin, TX.


Here's Why You Should Retain Hologic (HOLX) Stock for Now
January 4, 2022 |  finance.yahoo.com
STERIS (STE) Plans Sale of Non-Core Arm for Debt Repayment
December 22, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$42.05 million
Book Value
$0.26 per share


Net Income
$-22.61 million
Pretax Margin




Free Float
Market Cap
$169.63 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Confirmed)
Fiscal Year End


Overall MarketRank

2.30 out of 5 stars

Medical Sector

280th out of 1,405 stocks

Surgical & Medical Instruments Industry

30th out of 130 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -

Apollo Endosurgery (NASDAQ:APEN) Frequently Asked Questions

Is Apollo Endosurgery a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Apollo Endosurgery in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Apollo Endosurgery stock.
View analyst ratings for Apollo Endosurgery
or view top-rated stocks.

How has Apollo Endosurgery's stock been impacted by COVID-19?

Apollo Endosurgery's stock was trading at $2.0650 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, APEN stock has increased by 186.2% and is now trading at $5.91.
View which stocks have been most impacted by COVID-19

Are investors shorting Apollo Endosurgery?

Apollo Endosurgery saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 842,400 shares, an increase of 38.4% from the December 15th total of 608,700 shares. Based on an average daily volume of 288,900 shares, the days-to-cover ratio is currently 2.9 days. Currently, 5.3% of the company's shares are sold short.
View Apollo Endosurgery's Short Interest

When is Apollo Endosurgery's next earnings date?

Apollo Endosurgery is scheduled to release its next quarterly earnings announcement on Tuesday, February 22nd 2022.
View our earnings forecast for Apollo Endosurgery

How were Apollo Endosurgery's earnings last quarter?

Apollo Endosurgery, Inc. (NASDAQ:APEN) released its quarterly earnings data on Sunday, October, 31st. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.28) by $0.05. The biotechnology company had revenue of $16.35 million for the quarter, compared to analysts' expectations of $16.20 million. Apollo Endosurgery had a negative trailing twelve-month return on equity of 589.59% and a negative net margin of 29.80%. During the same quarter last year, the business earned ($0.11) EPS.
View Apollo Endosurgery's earnings history

What guidance has Apollo Endosurgery issued on next quarter's earnings?

Apollo Endosurgery issued an update on its FY 2021 earnings guidance on Thursday, November, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $63 million-$64 million, compared to the consensus revenue estimate of $62.72 million.

What price target have analysts set for APEN?

5 brokers have issued twelve-month price objectives for Apollo Endosurgery's shares. Their forecasts range from $12.00 to $15.00. On average, they anticipate Apollo Endosurgery's share price to reach $13.60 in the next twelve months. This suggests a possible upside of 130.1% from the stock's current price.
View analysts' price targets for Apollo Endosurgery
or view top-rated stocks among Wall Street analysts.

Who are Apollo Endosurgery's key executives?

Apollo Endosurgery's management team includes the following people:
  • Charles S. McKhann, President, Chief Executive Officer & Director
  • John Molesphini, Executive Vice President-Operations
  • Jeffrey G. Black, Chief Financial Officer (LinkedIn Profile)
  • Christopher J. Gostout, Chief Medical Officer
  • Tiffanie Gilbreth, Vice President-Clinical & Medical Affairs

What other stocks do shareholders of Apollo Endosurgery own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Apollo Endosurgery investors own include Obalon Therapeutics (OBLN), Novavax (NVAX), Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), OPKO Health (OPK), Pfizer (PFE), Sunesis Pharmaceuticals (SNSS), Biocept (BIOC), Co-Diagnostics (CODX) and Second Sight Medical Products (EYES).

What is Apollo Endosurgery's stock symbol?

Apollo Endosurgery trades on the NASDAQ under the ticker symbol "APEN."

How do I buy shares of Apollo Endosurgery?

Shares of APEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Apollo Endosurgery's stock price today?

One share of APEN stock can currently be purchased for approximately $5.91.

How much money does Apollo Endosurgery make?

Apollo Endosurgery has a market capitalization of $169.63 million and generates $42.05 million in revenue each year. The biotechnology company earns $-22.61 million in net income (profit) each year or ($0.65) on an earnings per share basis.

How many employees does Apollo Endosurgery have?

Apollo Endosurgery employs 158 workers across the globe.

What is Apollo Endosurgery's official website?

The official website for Apollo Endosurgery is www.apolloendo.com.

Where are Apollo Endosurgery's headquarters?

How can I contact Apollo Endosurgery?

Apollo Endosurgery's mailing address is 1120 SOUTH CAPITAL OF TX HWY BUILDING 1 SUITE 300, AUSTIN TX, 78746. The biotechnology company can be reached via phone at (512) 279-5100, via email at [email protected], or via fax at 858-678-0900.

This page was last updated on 1/17/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.